TECH · Intrinsic value
Is Bio-Techne Corporation (TECH) overvalued or undervalued?
Bio-Techne Corporation (TECH) trades at the delayed market price of $72.52 a share. That price already implies revenue growth of more than 25%/yr. TickerWorth's fair value is $25.09 a share (189% above fair value), as of Oct 19, 2026. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is TECH overvalued?
- Fair value
- $25.09
- Market price
- $72.52
- Downside to fair value
- 65.4%
- Verdict
- 189% above fair value
Reverse DCF: Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast.
What is TECH's TickerWorth Score?
Expensive vs our estimate — the business scores well
Compared with Healthcare companies in US
Its strongest point: recent price trend has been strong. Its weakest: trades above our estimate of what it's worth.
- Value · 26 of 100
Cheaper than 26% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 67 of 100
More profitable than 67% of Healthcare companies in US
- Financial health · 68 of 100
Financially stronger than 68% of Healthcare companies in US
- Growth · 47 of 100
Growing faster than 47% of Healthcare companies in US
- Momentum · 85 of 100
Outperformed 85% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
TECH DCF valuation: what the price assumes
At a recent price of $72.52, Bio-Techne Corporation (TECH) trades 189% above TickerWorth's blended fair value of $25.09 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices TECH overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -65.4% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values TECH at about $16.66 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Bio-Techne Corporation's projected free cash flows at a weighted-average cost of capital (WACC) of 11.1%, with a long-run terminal growth rate of 2.5%. About 68% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — TECH would need sustained revenue growth of more than 25%/yr to justify today's price, against about 4.3% a year compounded in our base case. We don't quote a precise figure here, because past about 25% a year the reverse-DCF stops being informative: it solves for revenue growth alone, holding margins, capital intensity and the forecast horizon fixed, so a price well above our fair value has nowhere to go but growth. The honest reading is that the price implies growth this model can't reconcile — not that we forecast it.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, TECH's modeled DCF value ranges from about $13.35 to $22.62 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Bio-Techne Corporation would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of TECH's intrinsic value. Figures update as new filings and prices come in.
Every input behind TECH's DCF
| Input | Value |
|---|---|
| Base-year revenueBIO-TECHNE Corp FY2026 10-K (accession 0001104659-26-100322): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2026 full year. | $1,215,040,000 |
| Base EBIT marginBIO-TECHNE Corp FY2026 10-K (accession 0001104659-26-100322): us-gaap:OperatingIncomeLoss 251,890,000 / revenue 1,215,039,000 = 20.73%, FY2026. | 20.7% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 5% → 4% → 4% → 4% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.27 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesBIO-TECHNE Corp FY2026 10-K (accession 0001104659-26-100322): WeightedAverageNumberOfDilutedSharesOutstanding = 157,009,000 shares, FY2026. | 157M |
| Market priceDelayed quote · as of 2026-10-19 17:01 UTC | $72.52 |
Change TECH's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Bio-Techne Corporation do?
What does it do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 3,000 people.
How does it make money?
The business turns $1.2B in annual revenue into profit. Out of every $100 of sales, about $28 is left as operating profit (operating margin of 27.9%), after a 66% gross margin on the products/services it sells. After all costs, taxes and interest, 15.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (4.5× current ratio), and is currently profitable.
Who at TECH filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| HIGGINS JOHN L | Director | Option exercise | — | Form 4 for HIGGINS JOHN L (opens sec.gov in a new tab) | |
| HIGGINS JOHN L | Director | Shares withheld (tax) | $403,300.62 | Form 4 for HIGGINS JOHN L (opens sec.gov in a new tab) | |
| BAUMGARTNER ROBERT V | Director | Option exercise | — | Form 4 for BAUMGARTNER ROBERT V (opens sec.gov in a new tab) | |
| BAUMGARTNER ROBERT V | Director | Shares withheld (tax) | $403,305.45 | Form 4 for BAUMGARTNER ROBERT V (opens sec.gov in a new tab) | |
| Geist William | PRESIDENT, PROTEIN SCIENCES | Option exercise | — | Form 4 for Geist William (opens sec.gov in a new tab) | |
| Geist William | PRESIDENT, PROTEIN SCIENCES | Shares withheld (tax) | $143,062.40 | Form 4 for Geist William (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is TECH's intrinsic value?
TickerWorth's blended fair value for Bio-Techne Corporation (TECH) is $25.09 per share, versus a market price of $72.52 (189% above fair value).
Is TECH overvalued or undervalued?
On our blended fair value TECH looks overvalued vs fair value at $72.52. This is an educational estimate, not advice.
What discount rate is used for TECH?
A WACC of 11.1% and a terminal growth rate of 2.5%.
Is Bio-Techne stock undervalued?
TickerWorth's fair value for Bio-Techne Corporation (TECH) is $25.09 against a market price of $72.52. Our read: 189% above fair value. This is a model estimate, not investment advice.
Bio-Techne (TECH) DCF valuation and fair value
Our fair value for Bio-Techne Corporation (TECH) is $25.09, built on a 11.1% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Bio-Techne stock?
Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $72.52. A model estimate, not investment advice.
Bio-Techne (TECH) insider trading
The most recent insider filing (SEC Form 4) for Bio-Techne Corporation (TECH): HIGGINS JOHN L, Director, option exercise on 2026-09-28. The latest filings are listed on this page. A disclosure, not a signal to trade.
Stocks below our fair value instead
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.